SKB-394

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug NameSKB-394
Drug Alias Nameanti-BCMA CAR T-cell therapy (Sichuan Kelun-Biotech Biopharmaceutical)SKB-394-BSKB-394
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsTumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A